Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Nanomedicine
- Vol. ume 16, 4451-4470
- https://doi.org/10.2147/ijn.s314367
Abstract
Background: Liver fibrosis is a chronic liver disease with excessive production of extracellular matrix proteins, leading to cirrhosis, hepatocellular carcinoma, and death. Purpose: This study aimed at the development of a novel derivative of polyethyleneimine (PEI) that can effectively deliver transforming growth factor β (TGFβ) siRNA and inhibit chemokine receptor 4 (CXCR4) for TGFβ silencing and CXCR4 Inhibition, respectively, to treat CCl4-induced liver fibrosis in a mouse model. Methods: Cyclam-modified PEI (PEI-Cyclam) was synthesized by incorporating cyclam moiety into PEI by nucleophilic substitution reaction. Gel electrophoresis confirmed the PEI-Cyclam polyplex formation and stability against RNAase and serum degradation. Transmission electron microscopy and zeta sizer were employed for the morphology, particle size, and zeta potential, respectively. The gene silencing and CXCR4 targeting abilities of PEI-Cyclam polyplex were evaluated by luciferase and CXCR4 redistribution assays, respectively. The histological and immunohistochemical staining determined the anti-fibrotic activity of PEI-Cyclam polyplex. The TGFβ silencing of PEI-Cyclam polyplex was authenticated by Western blotting. Results: The 1H NMR of PEI-Cyclam exhibited successful incorporation of cyclam content onto PEI. The PEI-Cyclam polyplex displayed spherical morphology, positive surface charge, and stability against RNAse and serum degradation. Cyclam modification decreased the cytotoxicity and demonstrated CXCR4 antagonistic and luciferase gene silencing efficiency. PEI-Cyclam/siTGFβ polyplexes decreased inflammation, collagen deposition, apoptosis, and cell proliferation, thus ameliorating liver fibrosis. Also, PEI-Cyclam/siTGFβ polyplex significantly downregulated α-smooth muscle actin, TGFβ, and collagen type III. Conclusion: Our findings validate the feasibility of using PEI-Cyclam as a siRNA delivery vector for simultaneous TGFβ siRNA delivery and CXCR4 inhibition for the combined anti-fibrotic effects in a setting of CCl4-induced liver fibrosis.Keywords
This publication has 89 references indexed in Scilit:
- Deadly liaisons: fatal attraction between CCN matricellular proteins and the tumor necrosis factor family of cytokinesJournal of Cell Communication and Signaling, 2009
- Cationic Nanoparticles Induce Nanoscale Disruption in Living Cell Plasma MembranesThe Journal of Physical Chemistry B, 2009
- Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapiesJournal of Hepatology, 2009
- Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1α-mediated stellate cell activationJournal of Hepatology, 2009
- TGFβ‐mediated BIM expression and apoptosis are regulated through SMAD3‐dependent expression of the MAPK phosphatase MKP2EMBO Reports, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingProceedings of the National Academy of Sciences of the United States of America, 2007
- Killing the messenger: short RNAs that silence gene expressionNature Reviews Molecular Cell Biology, 2003
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- RNA interferenceNature, 2002